Top-News
Trinity Biotech an Nasdaq , kleiner Hopfer nach oben? o.T.
Beiträge:
9
Zugriffe: 2.815 / Heute: 2
Zugriffe: 2.815 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers LevDAX Daily Swap UCITS ETF 1C
Perf. 12M: +59,80%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +52,93%
Xtrackers MSCI China UCITS ETF 1D
Perf. 12M: +46,29%
Xtrackers MSCI China UCITS ETF 1C
Perf. 12M: +45,84%
Trinity Biotech Receives FDA Clearance for the Macra(R) Lp(a) for use on Automated Systems
DUBLIN, Ireland, Jan. 20 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) today announced that it has received Food and Drug
Administration (FDA) marketing clearance for the Macra(R) Lp(a) assay for use on automated systems. The Macra(R) Lp(a) assay is a
microtitre plate assay used to measure the lipoprotein (a) contained in human serum. The test is distributed in the United States through
Wampole Laboratories, a division of New York City based Carter-Wallace, Inc. (NYSE: CAR).
Recent studies have identified Lp(a) as a significant risk factor for the development of coronary heart disease (CHD). Excess Lp(a) has
been associated with premature myocardial infarction and death among individuals with a family history of heart disease. The Macra(R)
Lp(a) assay is the only method cleared by the FDA for both diagnosis and risk assessment of CHD and it is now cleared for use on
automated systems. Prior to this clearance, Macra(R) was approved for manual use and was distributed through Wampole. The automated
systems market is considerably larger than the manual tests market, and this clearance improves the selling opportunities for the test.
Cardiovascular diseases (CVD) are the leading causes of death in the United States. Even for women, CVD cause many more deaths than
all cancers combined, including breast cancer. 58 million Americans have one or more types of CVD, including 14 million with CHD. At
least 250,000 people a year die of CHD within one hour of the onset of symptoms and before they reach the hospital. Lp(a) studies have
been described as "Powerful Predictors of Premature CHD in Selected Populations" and is the same test used in the renowned
Framingham Offspring Study.
"Trinity recognises the important role that automated systems play for the future of microtitre plate assays" commented, Ronan O'Caoimh,
Trinity Biotech's Chairman and CEO. "We feel it is important to ensure that our assays are certified for a variety of laboratory settings,
whether a small manual laboratory or a large, fully automated laboratory. The market for automated systems is expected to continue to
grow rapidly over the next several years. Trinity is committed to being a part of that growth opportunity by ensuring that our assays are
adapted for use on these automated systems."
Trinity Biotech acquired the Macra(R) Lp(a) assay in 1998 from Strategic Diagnostics, Inc. (Nasdaq: SDIX).
Trinity Biotech develops, manufactures, and markets over 100 diagnostic products for the point-of-care, self-testing, and clinical laboratory
segments of the diagnostic market. Trinity sells world-wide in over 80 countries through over 280 international distributors and strategic
partners.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the
results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other
agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed
in the Company's periodic reports filed with the Securities and Exchange Commission.
TGK
DUBLIN, Ireland, Jan. 20 /PRNewswire/ -- Trinity Biotech plc (Nasdaq: TRIBY) today announced that it has received Food and Drug
Administration (FDA) marketing clearance for the Macra(R) Lp(a) assay for use on automated systems. The Macra(R) Lp(a) assay is a
microtitre plate assay used to measure the lipoprotein (a) contained in human serum. The test is distributed in the United States through
Wampole Laboratories, a division of New York City based Carter-Wallace, Inc. (NYSE: CAR).
Recent studies have identified Lp(a) as a significant risk factor for the development of coronary heart disease (CHD). Excess Lp(a) has
been associated with premature myocardial infarction and death among individuals with a family history of heart disease. The Macra(R)
Lp(a) assay is the only method cleared by the FDA for both diagnosis and risk assessment of CHD and it is now cleared for use on
automated systems. Prior to this clearance, Macra(R) was approved for manual use and was distributed through Wampole. The automated
systems market is considerably larger than the manual tests market, and this clearance improves the selling opportunities for the test.
Cardiovascular diseases (CVD) are the leading causes of death in the United States. Even for women, CVD cause many more deaths than
all cancers combined, including breast cancer. 58 million Americans have one or more types of CVD, including 14 million with CHD. At
least 250,000 people a year die of CHD within one hour of the onset of symptoms and before they reach the hospital. Lp(a) studies have
been described as "Powerful Predictors of Premature CHD in Selected Populations" and is the same test used in the renowned
Framingham Offspring Study.
"Trinity recognises the important role that automated systems play for the future of microtitre plate assays" commented, Ronan O'Caoimh,
Trinity Biotech's Chairman and CEO. "We feel it is important to ensure that our assays are certified for a variety of laboratory settings,
whether a small manual laboratory or a large, fully automated laboratory. The market for automated systems is expected to continue to
grow rapidly over the next several years. Trinity is committed to being a part of that growth opportunity by ensuring that our assays are
adapted for use on these automated systems."
Trinity Biotech acquired the Macra(R) Lp(a) assay in 1998 from Strategic Diagnostics, Inc. (Nasdaq: SDIX).
Trinity Biotech develops, manufactures, and markets over 100 diagnostic products for the point-of-care, self-testing, and clinical laboratory
segments of the diagnostic market. Trinity sells world-wide in over 80 countries through over 280 international distributors and strategic
partners.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the
results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other
agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed
in the Company's periodic reports filed with the Securities and Exchange Commission.
TGK
...hat mir mein Kumpel aus der Bank erzählt, das die schon lange an einem Selbst-Test für HIV arbeiten, aber noch nicht das richtige gefunden haben. Sollten die als erste einen HIV-Home-Test entwickeln, kann man eigentlich gar nicht sagen, was mit der Aktie passiert, nur erahnen. Aber wie gesagt, die sollen da schon länger dran rumbasteln.
Haben kürzlich erst die Zulassung für einen Heliobacter Pylorus Schnelltest in USA bekommen , damit kann man Magengeschwüre / Gastitis OHNE SCHLAUCH , einfach mit einem Tropfen Blut diagnostizieren .... ich komme aus der Branche ,der Mensch macht im Leben 1 bis 2 Gastroskopien ,eine der unangenehmsten Diagnoseverfahren ,die es gibt ....
DER TEST IN EIN SEGEN FÜR DIE MENSCHEN ; WEIL MAN KEINEN SCHLAUCH MEHR SCHLUCKEN MUß; UND WIRD EIN SEGEN FÜR ALLE TRIBY AKTIONÄRE ::::
Der Rapit Test wird der Bluckbuster werden ..........Zulassung wohl 1 oder 2 Q .
Ende Feb kommen Zahlen , die werden bombig werden , rechnet mit 100 % Gewinnsteigerung !!!, das muß man sich mal vorstellen...
DER TEST IN EIN SEGEN FÜR DIE MENSCHEN ; WEIL MAN KEINEN SCHLAUCH MEHR SCHLUCKEN MUß; UND WIRD EIN SEGEN FÜR ALLE TRIBY AKTIONÄRE ::::
Der Rapit Test wird der Bluckbuster werden ..........Zulassung wohl 1 oder 2 Q .
Ende Feb kommen Zahlen , die werden bombig werden , rechnet mit 100 % Gewinnsteigerung !!!, das muß man sich mal vorstellen...
Es gibt keine neuen Beiträge.
Neueste Beiträge aus dem MAN St Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
3 | 35 | Volvo läßt es kräftig brummen. | Peddy78 | Highländer49 | 29.01.25 10:41 | |
| 7 | 786 | MAN - da geht was | pastorana | Paretorix | 03.03.22 21:42 | |
| +++Morgenbericht mit Terminen+Analysten 23.01.07+ | eposter | 25.04.21 11:14 | ||||
| +++Morgenbericht mit Terminen+Analysten 01.03.07+ | eposter | 25.04.21 11:08 | ||||
| 2 | 6 | Farbe ROT , oder was ist NORMAL ....... | Lalapo | Timchen | 25.04.21 11:04 |
